PMID- 35660631
OWN - NLM
STAT- MEDLINE
DCOM- 20220809
LR  - 20220907
IS  - 1873-4995 (Electronic)
IS  - 0168-3659 (Linking)
VI  - 348
DP  - 2022 Aug
TI  - Nano co-delivery of Plumbagin and Dihydrotanshinone I reverses immunosuppressive 
      TME of liver cancer.
PG  - 250-263
LID - S0168-3659(22)00328-5 [pii]
LID - 10.1016/j.jconrel.2022.05.057 [doi]
AB  - Hepatocellular carcinoma (HCC) is resistant to current immunotherapy. This poor 
      outcome mainly results from the immunosuppressive characteristics of tumor 
      microenvironment (TME). Accumulating evidence indicates that some chemotherapy 
      agents trigger immunogenic cell death (ICD), providing a promising strategy to 
      remodel the immunosuppressive TME. The role of Plumbagin (PLB, a naphthoquinone 
      compound from Plumbago zeylanica L.) as the ICD inducer for HCC cells was 
      confirmed in this study. Dihydrotanshinone I (DIH, a phenanthraquinone compound 
      of Salvia miltiorrhiza) functioned as the ICD enhancer by generating the reactive 
      oxygen species (ROS). A poly(D,L-lactic-co-glycolic acid) (PLGA)-based 
      nanoparticle (NP) was used to co-encapsulate PLB, DIH and NH(4)HCO(3) (a pH 
      sensitive adjuvant). This NP was further coated with the mannose-inserted 
      erythrocyte membrane to produce a nanoformulation. This nanoformulation 
      significantly increased the half-life and tumor targeting of two drugs in 
      orthotopic HCC mice, generating chemo-immunotherapeutic effects for reversal of 
      immunosuppressive TME. Consequently, the biomimetic nanoformulation loaded with 
      low doses of PLB and DIH achieved significantly longer survival of HCC mice, 
      without causing toxic signs. Our study demonstrates a promising strategy for 
      remodeling the immunosuppressive TME of liver cancer.
CI  - Copyright (c) 2022 Elsevier B.V. All rights reserved.
FAU - Han, Shulan
AU  - Han S
AD  - School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.
FAU - Bi, Shengnan
AU  - Bi S
AD  - Department of Pharmacy, the Affiliated Hospital to Changchun University of 
      Chinese Medicine, Changchun 130021, China.
FAU - Guo, Tingting
AU  - Guo T
AD  - Department of Pharmacy, the Affiliated Hospital to Changchun University of 
      Chinese Medicine, Changchun 130021, China.
FAU - Sun, Dandan
AU  - Sun D
AD  - School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.
FAU - Zou, Yifang
AU  - Zou Y
AD  - School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.
FAU - Wang, Lingzhi
AU  - Wang L
AD  - School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.
FAU - Song, Liu
AU  - Song L
AD  - School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.
FAU - Chu, Di
AU  - Chu D
AD  - School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.
FAU - Liao, Anqi
AU  - Liao A
AD  - School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.
FAU - Song, Xiaohuan
AU  - Song X
AD  - School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.
FAU - Yu, Zhuo
AU  - Yu Z
AD  - Department of Hepatopathy, Shuguang Hospital, Affiliated to Shanghai University 
      of Traditional Chinese Medicine, Shanghai 201203, China. Electronic address: 
      zhuoyu@shutcm.edu.cn.
FAU - Guo, Jianfeng
AU  - Guo J
AD  - School of Pharmaceutical Sciences, Jilin University, Changchun 130021, China; 
      Third-Grade Laboratory of Chinese Medicine Chemistry, National Administration of 
      Traditional Chinese Medicine, Jilin University, Changchun 130021, China; Jilin 
      Provincial Key Experiment Education Center for Pharmaceutical Sciences, Jilin 
      University, Changchun 130021, China. Electronic address: jguo@jlu.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220608
PL  - Netherlands
TA  - J Control Release
JT  - Journal of controlled release : official journal of the Controlled Release 
      Society
JID - 8607908
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Furans)
RN  - 0 (Naphthoquinones)
RN  - 0 (Phenanthrenes)
RN  - 0 (Quinones)
RN  - 33X04XA5AT (Lactic Acid)
RN  - 562G9360V6 (dihydrotanshinone I)
RN  - YAS4TBQ4OQ (plumbagin)
SB  - IM
MH  - Animals
MH  - *Antineoplastic Agents
MH  - *Carcinoma, Hepatocellular/pathology
MH  - Cell Line, Tumor
MH  - Furans
MH  - Lactic Acid/chemistry
MH  - *Liver Neoplasms/metabolism
MH  - Mice
MH  - *Nanoparticles/chemistry
MH  - *Naphthoquinones/chemistry/therapeutic use
MH  - Phenanthrenes
MH  - Quinones
MH  - Tumor Microenvironment
OTO - NOTNLM
OT  - Biomimetic nanoformulation
OT  - Combination therapy
OT  - Hepatocellular carcinoma
OT  - Traditional herbal medicine
OT  - cancer immunotherapy
EDAT- 2022/06/07 06:00
MHDA- 2022/08/10 06:00
CRDT- 2022/06/06 11:42
PHST- 2022/04/01 00:00 [received]
PHST- 2022/05/23 00:00 [revised]
PHST- 2022/05/30 00:00 [accepted]
PHST- 2022/06/07 06:00 [pubmed]
PHST- 2022/08/10 06:00 [medline]
PHST- 2022/06/06 11:42 [entrez]
AID - S0168-3659(22)00328-5 [pii]
AID - 10.1016/j.jconrel.2022.05.057 [doi]
PST - ppublish
SO  - J Control Release. 2022 Aug;348:250-263. doi: 10.1016/j.jconrel.2022.05.057. Epub 
      2022 Jun 8.